Prostate Cancer Prostate carcinoma
Conditions
Interventions
None listed
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Histologically proven primary cancer of the prostate, based on prostate biopsy-core analysis. - Patient is scheduled and fit for PSMA-PET/CT - Age*50 years. Ability to give voluntary written informed consent to participate in this study.
Exclusion criteria
Exclusion criteria: - Contraindication for MRI-scanning, i.e. claustrophobia, intracranial metal clips, metallic bodies in the eye, implanted electric and electronic devices not eligible for MRI (pacemakers, insulin pumps, cochlear implants, neurostimulators). - Prior prostate cancer treatment. - Prior pelvic surgery, associated with pelvic lymphadenopathy - Presence of any medical condition that in the opinion of the investigator/treating physician will affect patients* clinical status by participating in this trial. - Inability to lie still for 45 minutes or comply with imaging. - The patient is already enrolled in one or more concurrent studies, which could confound the results of this study, according to the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main parameter of this study is the feasibility of MRI, as a weighted score of combined quantitative MRI parameters, to predict the presence of lymph node metastases in prostate cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints comprise established thresholds in individual quantitative MRI parameters separating localized from (oligo-)metastatic disease. | — |
Countries
Netherlands
Outcome results
None listed